Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
in Preterm Infants
Michael P. Sherman, MD, PhD1, David H. Adamkin, MD2, Victoria Niklas, MD3,*, Paula Radmacher, PhD2, Jan Sherman, PhD1,4,
Fiona Wertheimer, DO3, and Karel Petrak, PhD5,
Objective To evaluate the safety and explore the efficacy of recombinant human lactoferrin (talactoferrin [TLf]) to
reduce infection.
Study design We conducted a randomized, double blind, placebo-controlled trial in infants with birth weight of
750-1500 g. Infants received enteral TLf (n = 60) or placebo (n = 60) on days 1 through 28 of life; the TLf dose was
150 mg/kg every 12 hours. Primary outcomes were bacteremia, pneumonia, urinary tract infection, meningitis, and
necrotizing enterocolitis (NEC). Secondary outcomes were sepsis syndrome and suspected NEC. We recorded clinical,
laboratory, and radiologic findings, along with diseases and adverse events, in a database used for statistical analyses.
Results Demographic data were similar in the 2 groups of infants. We attributed no enteral or organ-specific
adverse events to TLf. There were 2 deaths in the TLf group (1 each due to posterior fossa hemorrhage and postdischarge sudden infant death), and 1 death in the placebo group, due to NEC. The rate of hospital-acquired infections was 50% lower in the TLf group compared with the placebo group (P < .04), including fewer blood or line
infections, urinary tract infections, and pneumonia. Fourteen infants in the TLf group weighing <1 kg at birth had
no gram-negative infections, compared with only 3 of 14 such infants in the placebo group. Noninfectious outcomes
were not statistically significantly different between the 2 groups, and there were no between-group differences in
growth or neurodevelopment over a 1-year posthospitalization period.
Conclusion We found no clinical or laboratory toxicity and a trend toward less infectious morbidity in the infants
treated with TLf. (J Pediatr 2016;-:---).
Trial registration ClinicalTrials.gov: NCT00854633.
ospital-acquired infections represent the majority of diseases affecting preterm infants in neonatal intensive care units
(NICUs).1 Because hospital-acquired infections are associated with increased length of hospital stay and significant increases in the cost of care, the American Academy of Pediatrics has called for strategies to reduce hospital-acquired
infections in NICUs.2,3 Among hospital-acquired infections, bacteria resistant to broad-spectrum antibiotics cause >50% of
patient-associated diseases,4 which has led to an emphasis on antibiotic stewardship.
Modified health care practices have reduced hospital-acquired infections in extremely preterm infants,2,3 but do not address
the underlying immaturity of the mucosal and systemic immune systems.5 Maternal milk is known to reduce the occurrence of
bacteremia and necrotizing enterocolitis (NEC).6,7 Biomolecules in human milk are proposed to synchronously modify the
intestinal microbiome and nascent gut and boost systemic immunity, thereby reducing susceptibility to infection.5,8 Extremely
preterm infants (birth weight <1 kg) are the most vulnerable to infection because maternal colostrum is limited immediately
after birth, or because intestinal dysmotility hinders full enteral feedings for days to weeks.
Human milk proteins enhance the development of intestinal epithelia,
facilitate a healthy intestinal microflora, establish host defenses, and heighten
From the Division of Neonatology, Department of Child
mucosal defenses. We propose that the human milk protein lactoferrin partly
Health, University of Missouri, Columbia, MO; Division
explains these beneficial effects.9,10 Commercial recombinant human lactoferrin
of Neonatal Medicine, Department of Pediatrics,
University of Louisville, Louisville, KY; Division of
(talactoferrin [TLf]) TLf became available 20 years ago.11 We found that feeding
Neonatal Medicine, Childrens Hospital Los Angeles,
1
AE
bLF
CoNS
FDA
IND
NEC
NICU
RCT
SAE
TLf
VLBW
Adverse event
bovine lactoferrin
Coagulase-negative staphylococci
Food and Drug Administration
Investigational New Drug
Necrotizing enterocolitis
Neonatal intensive care unit
Randomized controlled trial
Serious adverse event
Talactoferrin
Very low birth weight
www.jpeds.com
Methods
In this double-blinded RTC, TLf or placebo was administered
to infants with birth weight between 750 and 1500 g starting
within 24 hours of birth and continuing through 28 days of
life (ClinicalTrials.gov: NCT00854633). We excluded infants
who had a major congenital malformation, chromosomal abnormality, documented prenatal or intrapartum neonatal
infection, or absence of parental consent, or were moribund
at birth. We enrolled and randomized subjects between July
1, 2009, to March 17, 2012. Hospital discharge was followed
by a 1-year outpatient follow-up period. Agennix Inc (Houston, Texas), the trial sponsor, ended the final data analyses in
December 2013.
Agennix provided TLf to 3 academic health care systems in
the US. Agennix used good manufacturing practice and suspended TLf in sterile, endotoxin-free, phosphate-buffered saline. The excipient served as the placebo with excellent color
matching. The Institutional Review Board for each site
approved the study. We obtained written consent from the
parents or legal guardians before 24 hours of age. Thereafter,
each institutional pharmacy randomized a subject via a central computer system (inVentiv Clinical Solutions, Houston,
Texas). The inVentiv Web Response system also recorded
data about participants in this RCT. Agennix sponsored the
research under Food and Drug Administration (FDA) Investigational New Drug (IND) policies and procedures. The
study design included a Data Safety Monitoring Board, a
centralized serious adverse event reporting system, and periodic onsite monitoring visits that verified clinical, health
care, laboratory, and radiologic data and pharmacy record
keeping.
We randomized infants to receive either TLf solution
(150 mg/mL) at a dose of 300 mg/kg/day or an identical volume of the excipient. Doses were administered every 12 hours
via nasogastric tube from days of life 1 through 28 or until
discharge, whichever occurred first. We extrapolated the
dose of TLf from lactoferrin consumed during enteral breast
milk feeding (150 mL/kg/day) with the content of lactoferrin
in human milk estimated at 2 mg/mL. In all subjects, we
administered the first dose before 24 hours of age. We
adjusted the dose at weekly intervals if the weight increased
by $10% from a previous weight.
Primary and Secondary Outcomes
The primary outcome was a significant reduction in hospitalacquired infections, including bacteremia, pneumonia, urinary tract infection, meningitis, and NEC. Our criteria
were based on Centers for Disease Control and Prevention
2
- 2016
ORIGINAL ARTICLES
Results
Table I presents demographic data for the preterm infants and
mothers associated with the clinical trial. Mothers declared
their decision regarding breast milk or formula feeding
during the consent process. The pharmacy considered each
mothers feeding decision during randomization. Thus, the
assignments were equal in the TLf vs placebo and enteral
nutrition with mothers milk and formula. Human donor
milk was not used during the trial.
The Figure (available at www.jpeds.com) presents a
CONSORT diagram of the study. Thirty-seven of 60 infants
(62%) completed the entire 28-day TLf treatment course, and
44 of 60 infants (73%) completed the entire placebo arm.
One infant assigned to the TLf arm died of brain stem
hemorrhage at 30 hours of age and was excluded from the
outcome assessment. One infant in the TLf arm died of
sudden infant death syndrome after discharge, and 1 infant in
TLf group
(n = 60)
14 (23)
Birth weight 750-1000 g, n (%)
46 (75)
Birth weight 1001-1500 g, n (%)
9 (15)
Small for gestational age status, n (%)
33 (55)
Male sex, n (%)
z
5 and 8
Apgar score, 1 and 5 min, median
18 (30)
Multiple births, n (%)
42 (70)
Preterm labor, n (%)
19 (32)
Premature rupture of membranes, n (%)
8 (13)
>12-hour rupture of membranes, n (%)
32 (53)
Maternal antibiotics, n (%)
48 (80)
One or more doses of betamethasone, n (%)
49/11
Cesarean/vaginal delivery, n
Race/ethnicity, n
White
36
African American
5
Asian
1
Multiracial
5
Hispanic
13
Placebo group
(n = 60)
28 6/7
1143 220
14 (23)
46 (75)
11 (18)
36 (60)
7 and 8
13 (22)
41 (68)
21 (35)
15 (25)
35 (58)
45 (75)
48/12
33
11
0
4
12
NICU stay (relative risk, 0.52; 95% CI, 0.26-0.99; P < .045).
There were no cases of meningitis in either group. Two
infants in the TLf group developed NEC, both of whom
survived, and 1 formula-fed infant in the placebo group
died from NEC.
Table VI lists the types of bacteria that caused the
infections. In the TLf group, there was a reduction in
gram-positive bacterial isolates, with coagulase-negative
staphylococci (CoNS) accounting for most of these isolates.
In 14 infants with birth weight <1 kg, we identified no
cases of gram-negative bacterial infection and 2 cases of
CoNS-related bacteremia (14%). In the placebo group, 5 of
14 infants (36%) with birth weight <1 kg had bacteremia
caused by CoNS (n = 2) or Klebsiella pneumoniae (n = 1),
or pneumonia caused by Klebsiella oxytoca (n = 2).
Total,
n (%)
Volume -
www.jpeds.com
TLf
Placebo
P
group, n (%) group, n (%) value
58 (97)
27 (45)
60 (100)
25 (42)
.99
.91
7 (12)
0
8 (13)
0
.95
-
14 (23)
8 (13)
.33
53 (88)
5 (8)
53 (88)
7 (12)
.94
.83
14 (23)
17 (28)
25 (42)
1 (2)
1 (2)
2
0
15 (25)
20 (33)
21 (35)
3 (5)
1 (2)
1
0
.94
.84
.83
.65
.48
1.0
-
MedDRA Version 14.1 defined classes, organ systems, and preferred terms. Scoring criteria are
available at http://www.meddra.org/.
Discussion
To date, 4 investigative groups have published clinical trial
information using enteral administration of bovine lactoferrin (bLF) to prevent late-onset sepsis and NEC during hospitalization of infants with birth weight #2000 g.17-20 The
current RCT is a Phase 1/2 trial that provides safety and preliminary efficacy data associated with enteral administration
TLf group
(n = 59)
Placebo group
(n = 60)
RR (% CI)
NNT
P value
10 (17)
6 (10)
0 (0)
20 (33)
10 (17)
5 (8)
0.52 (0.26-0.99)
0.64 (0.3-1.7)
0.10 (0.01-1.8)
6
14
13
<.04
.52
.09
2 (3)
4 (7)
0.52 (0.1-2.8)
25
.72
2 (3)
1 (2)
0.23 (0.1-1.0)
61
3460
2.0
3446
4.4
0.52 (0.1-2.8)
25
1.0
NS
.10
NNT, number needed to treat; NS, not significant; RR, relative risk.
*The number of hospital-acquired infections/total number of infants per group.
P value from c2 test for infectious comparisons; hospital-acquired infection/1000 hospital days from t test; significance P # .05.
zFirst identified episode of hospital-acquired infection in bloodstream, spinal fluid, urine, and lung fluid.
Sherman et al
- 2016
ORIGINAL ARTICLES
TLf vs placebo
Bacterial isolate*
TLf group
(n/N = 8/59; 14%), n/N (%)
Placebo group
(n/N = 20/60; 33%), n/N (%)
RR (95% CI)
NNT
P valuez
Gram-negative bacteria
Gram-positive bacteria
CoNS per gram-positive infectionx
4/8 (50)
4/8 (50)
3/4 (75)
5/20 (25)
15/20 (75)
11/15 (73)
1.6 (0.5-4.8)
0.76 (0.3-1.8)
0.74 (0.3-2.2)
8
3
5
.96
.04
.09
*All n are based on the type of bacteria identified by Gram stain result and culture identification methods for the first episode of hospital-acquired infection.
Number of each type of infection/total number of study subjects by type (%).
zP values from the c2 test; significance P # .05.
xNumber of CoNS infections per total gram-positive bacterial infections.
of TLf. The study used a recombinant human lactoferrin produced under good manufacturing practices and with FDA
approval as an IND. This study also used the MedDRA system to measure safety during and after administration of
TLf, an instrument used by the International Conference
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.12 The results
demonstrate the safety of the TLf molecule and provide an
initial report of efficacy related to reducing hospitalacquired infections and possibly other noninfectiousrelated outcomes.
The 4 previous studies using bLF in preterm infants reported a reduced rate of infection of variable magnitude,
and 1 report using prophylaxis with bLF noted a reduction
in late-onset sepsis among infants with birth weight
<1 kg.17 In the current TLf trial, we found a 14% rate of infection in infants with birth weight <1 kg given enteral TLf vs
36% in babies given placebo. Our results are in agreement
with those reported by Manzoni et al,17 with a comparable
reduction in infection rates in extremely preterm infants.
In all studies using bLF, the biological agent was generally regarded as a safe food supplement. In contrast, the source of
TLf was biotechnology rather than a food supplement isolated from bovine milk. Furthermore, compared with the
aforementioned RCT using bLF,17 TLf showed similar therapeutic efficacy as bLf in reducing gram-positive bacterial infections (Table VI). We propose that this decline caused the
overall reduction in hospital-acquired infections in infants
treated with TLf compared with those treated with placebo
(Table IV).
There were no urinary tract infections in the TLf group
but some in the placebo group; however, the difference was
not statistically significant. An association between urinary
infections and NEC was reported recently.21 Because the
fecal microbiome is a microbial reservoir for urogenital
colonization, we suggest a possible relationship between
enteric prophylaxis with TLf and reduced urinary infections, and would encourage examination of this association
in upcoming clinical trials of bLF. Future studies of lactoferrin prophylaxis should study the fecal microbiome,
because the microbiota present may be transferred to other
body sites. Metagenomic technology can accurately classify
the fecal translocation of pathogenic bacteria originating in
the feces.22
References
1. Polin RA, Denson S, Brady MT. Epidemiology and diagnosis of health
care-associated infections in the NICU. Pediatrics 2012;129:e1104-9.
2. Bizzarro MJ, Shabanova V, Baltimore RS, Dembry LM, Ehrenkranz RA,
Gallagher PG. Neonatal sepsis 2004-2013: the rise and fall of coagulasenegative staphylococci. J Pediatr 2015;166:1193-9.
3. Polin RA, Denson S, Brady MT. Strategies for prevention of health careassociated infections in the NICU. Pediatrics 2012;129:e1085-93.
4. Cantey JB, Milstone AM. Bloodstream infections: epidemiology and
resistance. Clin Perinatol 2015;42:1-16.
5. Collado MC, Cernada M, Neu J, Perez-Martnez G, Gormaz M,
Vento M. Factors influencing gastrointestinal tract and microbiota immune interaction in preterm infants. Pediatr Res 2015;77:726-31.
6. Patel AL, Johnson TJ, Engstrom JL, Fogg LF, Jegier BJ, Bigger HR, et al.
Impact of early human milk on sepsis and health-care costs in very low
birth weight infants. J Perinatol 2013;33:514-9.
7. Sullivan S, Schanler RJ, Kim JH, Patel AL, Traw
oger R, KiechlKohlendorfer U, et al. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human
milk and bovine milk-based products. J Pediatr 2010;156:562-7.e1.
8. Neu J, Mihatsch WA, Zegarra J, Supapannachart S, Ding ZY, MurguaPeniche T. Intestinal mucosal defense system, Part 1. Consensus recommendations for immunonutrients. J Pediatr 2013;162(3 Suppl):S56-63.
9. Sherman MP, Adamkin DH, Radmacher PG, Sherman J, Niklas V. Protective proteins in mammalian milks: lactoferrin steps forward. Neoreviews 2012;13:e293-300.
www.jpeds.com
10. Jiang R, Du X, L
onnerdal B. Comparison of bioactivities of talactoferrin
and lactoferrins from human and bovine milk. J Pediatr Gastroenterol
Nutr 2014;59:642-52.
11. Ward PP, Piddington CS, Cunningham GA, Zhou X, Wyatt RD,
Conneely OM. A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic. Biotechnology (N
Y) 1995;13:498-503.
12. Edde L, Hipolito RB, Hwang FF, Headon DR, Shalwitz RA, Sherman MP.
Lactoferrin protects neonatal rats from gut-related systemic infection.
Am J Physiol Gastrointest Liver Physiol 2001;281:G1140-50.
13. McKibben L, Horan TC, Tokars JI, Fowler G, Cardo DM, Pearson ML,
et al. Guidance on public reporting of healthcare-associated infections:
recommendations of the Healthcare Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 2005;26:580-7.
14. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on
staging criteria. Pediatr Clin North Am 1986;33:179-201.
15. Brajovic S. MedDRA use at FDA. http://www.ich.org/fileadmin/Public_
Web_Site/Training/GCG-_Endorsed_Training_Events/ASEAN_MedDRA_
March_2010/Day_3/Regulatory_Perspective_SBrajovic.pdf. Accessed April
26, 2016.
16. Weiss LG, Oakland T, Aylward GP, Eds. Bayley III. Clinical use and
interpretation. Burlington, MA: Elsevier Inc.; 2010.
Volume 17. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al.
Bovine lactoferrin supplementation for prevention of late-onset sepsis in
very low-birth-weight neonates: a randomized trial. JAMA 2009;302:
1421-8.
18. Manzoni P, Meyer M, Stolfi I, Rinaldi M, Cattani S, Pugni L, et al. Bovine
lactoferrin supplementation for prevention of necrotizing enterocolitis
in very-low-birth-weight neonates: a randomized clinical trial. Early
Hum Dev 2014;90(Suppl 1):S60-5.
19. Akin IM, Atasay B, Dogu F, Okulu E, Arsan S, Karatas HD, et al. Oral
lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis
of premature neonates and effect on T-regulatory cells. Am J Perinatol
2014;31:1111-20.
20. Ochoa TJ, Zegarra J, Cam L, Llanos R, Pezo A, Cruz K, et al. Randomized
controlled trial of lactoferrin for prevention of sepsis in Peruvian neonates less than 2500 g. Pediatr Infect Dis J 2015;34:571-6.
21. Pineda LC, Hornik CP, Seed PC, Cotten CM, Laughon MM, Bidegain M,
et al. Association between positive urine cultures and necrotizing enterocolitis in a large cohort of hospitalized infants. Early Hum Dev 2015;91:
583-6.
22. Sherman MP, Minnerly J, Curtiss W, Rangwala S, Kelley ST. Research on
neonatal microbiomes: what neonatologists need to know. Neonatology
2014;105:14-24.
Sherman et al
- 2016
ORIGINAL ARTICLES
TLf group
(n = 60)
46 14
25 7
5461 4739
94.9
Placebo group
(n = 60)
49 10
26 5
6221.50 4999
96.0
6.e1
Volume -
www.jpeds.com
TLf group
(n = 59)
Placebo group
(n = 60)
P
value
19 4
16 2
.40
27 1
994 61
2 of 14 (14)
5 of 45 (11)
27 1
1003 58
8 of 14 (57)
6 of 46 (13)
.80
.92
.14
.96
n (%)
n (%)
P value
Suspected NEC
Neonatal sepsis syndrome or inflammatory response syndrome
Death
Other outcomes
45
45
45
45
6/46 (11)
3/46 (8)
3/60 (3)
11/46 (24)
46
46
46
46
8/46 (15)
1/46 (2)
0/60 (2)
11/46 (22)
.89
.61
.26
.89
Mean SD
Mean SD
P valuez
44
37
36
37
45
45
44
23 13
10 9
13 14
60 31
1702 20
46
46
30
35
46
46
55
20 15
99
19 19
59 29
1663 20
.26
.24
.76
.32
.83
.15
6.e2
Sherman et al
- 2016
ORIGINAL ARTICLES
n (%)
n (%)
P value
NEC scares
Neonatal sepsis syndrome or inflammatory response syndrome
Death
Other endpoints/outcomes
15
15
15
15
1 (8)
0 (0)
0 (0)
1 (8)
14
14
14
14
1 (7)
0 (0)
0 (0)
2 (14)
1.0
1.0
Mean SD
Mean SD
P valuez
15
13
8
13
15
13
45
16 8
69
16 10
51 22
1713 31
14
10
10
9
14
9
25
22 15
11 11
29 33
58 29
1710 30
.50
.58
.18
.48
.82
.94
6.e3